An Act to revise provisions regarding the medical marijuana oversight committee.

Be it enacted by the Legislature of the State of South Dakota:

Section 1. That § 34-20G-93 be AMENDED:

34-20G-93. The oversight committee shall meet at least two times per year for the purpose of evaluating and making recommendations to the Legislature and the department regarding:

(1) The ability of qualifying patients in all areas of the state to obtain timely access to high-quality medical cannabis;

(2) The effectiveness of the dispensaries and cultivation facilities, individually and together, in serving the needs of qualifying patients, including the provision of educational and support services by dispensaries, the reasonableness of their prices, whether they are generating any complaints or security problems, and the sufficiency of the number operating to serve the state's registered qualifying patients;

(3) The effectiveness of the cannabis testing facilities, including whether a sufficient number are operating;

(4) The sufficiency of the regulatory and security safeguards contained in this chapter and adopted by the department to ensure that access to and use of cannabis cultivated is provided only to cardholders;

(5) Any recommended additions or revisions to the department regulations or this chapter, including relating to security, safe handling, labeling, and nomenclature, employment, law enforcement, medical providers, review of medical complications and side effects, and other recommendations; and

(6) Any research studies regarding health effects of medical cannabis for patients.

Section 2. That § 34-20G-93, as amended by section 1 of this Act, is repealed on June 30, 2025.

Section 3. That § 34-20G-92 be REPEALED:

The Executive Board of the Legislative Research Council shall appoint an oversight committee comprised of: one member of the House of Representatives, one member of the Senate, one Department of Criminal Investigation agent, one staff member from the Office of the Attorney General, two representatives of law enforcement, one representative from the department, one practitioner with experience in medical cannabis issues, one nurse, one board member or principal officer of a cannabis testing facility, one person with experience in policy development or implementation in the field of medical cannabis, and three qualifying patients.

Section 4. That the repeal of § 34-20G-92 in section 3 of this Act is effective June 30, 2025.